Anti-idiotype antibodies and methods of using the same
AssigneeMustang Bio, Inc.
InventorsEkta PATEL, Junxia WANG, Ajit KAMATH, Nathan K GUMLAW
Life of this patent
Estimating the term…
Loading patent…
AssigneeMustang Bio, Inc.
InventorsEkta PATEL, Junxia WANG, Ajit KAMATH, Nathan K GUMLAW
Estimating the term…
The present disclosure relates generally to antibodies and binding fragments thereof that bind to anti-CD123 antibodies, chimeric antigen receptors (CARs), or antibody binding fragments. In particular, the disclosed anti-idiotype antibodies and fragments bind to anti-CD123 antibodies, CARs, or fragments thereof and comprise novel complementary determining regions (CDRs). Finally, the present disclosure relates to methods of using the disclosed antibodies and fragments thereof to expand and/or activate CD123-CAR-expressing immune cells, detecting or quantifying CD123-CARs, and isolating CD123-CAR-expressing immune cells.
An antibody or antigen-binding fragment comprising a heavy chain variable (VH) region and a light chain variable (VL) region, the VH and VL regions comprising a heavy chain complementarity determining region 1 (CDRH1) comprising GFNIKDSF (SEQ ID NO:
A nucleotide sequence encoding an antibody or antigen-binding fragment comprising:
A method of expanding or activating immune cells that express an anti-CD123 chimeric antigen receptor (CD123-CAR) comprising contacting in vitro a population of immune cells that express a CD123-CAR with an anti-idiotype antibody or antigen-binding fragment that specifically binds to an idiotype of the CD123-CAR, wherein the CD123-CAR comprises a scFv that binds to CD123, a hinge domain, a transmembrane domain, a co-stimulatory domain, and T cell receptor zeta chain signaling domain.
A method of detecting the presence of a CD123-CAR in a sample comprising, contacting a sample comprising immune cells that are suspected of expressing a CD123-CAR with an anti-idiotype antibody or antigen-binding fragment that specifically binds to an idiotype of the CD123-CAR and quantifying the number of cells expressing the CD123-CAR, wherein the CD123-CAR comprises a scFv that binds to CD123, a hinge domain, a transmembrane domain, at least one co-stimulatory domain, and T cell receptor zeta chain signaling domain.
A method of isolating immune cells that express an CD123-CAR from a sample comprising, contacting a sample comprising immune cells that are suspected of expressing an CD123-CAR with a solid support comprising an anti-idiotype antibody or antigen-binding fragment comprising:
Dependencies are inferred from the claim text.